Personalis, Inc. will present new data at the upcoming Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting, taking place in Washington, D.C., November 9-11, 2018.
MENLO PARK, Calif.--(BUSINESS WIRE)-- Personalis, Inc., a provider of advanced genomic sequencing and analytics for immuno-oncology, today announced that the company, along with one of their collaborators, Dr. Sekwon Jang of the Inova Cancer Center, will present new data at the upcoming Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting, taking place in Washington, D.C., November 9-11, 2018.
Following is a list of abstracts that will be presented at the meeting.
| Rapid Oral Abstract Presentation Session | |||||||||
| Session | Title & Presenter | Day & Time | Location | ||||||
| Rapid Oral Abstracts | Molecular profiling of anti-PD-1 treated melanoma patients reveals importance of assessing neoantigen burden and tumor escape mechanisms for clinical treatment | November 9: | 204ABC | ||||||
| Scientific Poster Presentations | |||||||||
| Poster Number & Session | Title & Presenter | Day & Time | Location | ||||||
| P13 | Molecular profiling of anti-PD-1 treated melanoma patients reveals importance of assessing neoantigen burden and tumor escape mechanisms for clinical treatment | November 9: | Hall E | ||||||
| P151 | Improving neoantigen identification for therapeutic and diagnostic use in immuno-oncology using mass spectrometry and machine learning | November 9: | Hall E | ||||||
| P78 | More sensitive identification of T-cell receptor beta rearrangements with an augmented transcriptome method | November 10: | Hall E | ||||||
Personalis will also be exhibiting during the conference (Booth #617). Representatives will be available to answer questions about the company’s cancer immunogenomics services.
About Personalis, Inc.
Personalis, Inc. is a leading precision medicine company focused on advanced NGS-based services for immuno-oncology and cancer for clinical trials and translational research. The Personalis ACE Exome and Transcriptome technology is designed to obtain the most comprehensive and accurate tumor molecular profile and each tumor’s unique immune microenvironment for immuno-oncology applications. The company’s Clinical Laboratory is GxP aligned as well as CLIA’88 and CAP accredited. Personalis is differentiated by advanced sequencing assays, algorithms and content for neoantigen characterization, customer regulatory support, and more. Visit our website at www.personalis.com and follow @PersonalisInc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181106006018/en/
Source: Personalis, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20181106006018/en
